From: Evaluation of markers of outcome in real-world treatment of diabetic macular edema
Functional non-responders (N = 26) | Early functional responders (N = 74) | Late functional responders (N = 22) | p-valuea | p-valueb | |
---|---|---|---|---|---|
BCVA (L) | |||||
Baseline | 65.3 ± 10.5 | 62.3 ± 13.2 | 63.8 ± 13.4 | 0.535 | 0.447 |
3 M | 63.9 ± 13.4 | 72.2 ± 11.0 | 65.1 ± 12.6 | 0.009 | 0.001 |
p-value 3 M | 0.506 | < 0.001 | 0.13 | ||
6 M | 64.7 ± 12.0 | 75.5 ± 9.6 | 72.7 ± 11.8 | < 0.001 | < 0.001 |
p-value 6 M | 0.847 | < 0.001 | < 0.001 | ||
CRT (μm) | |||||
Baseline | 420.7 ± 99.1 | 435.8 ± 109.5 | 434.9 ± 111.1 | 0.563 | 0.553 |
3 M | 346.9 ± 90.3 | 334.4 ± 62.0 | 348.3 ± 86.7 | 0.712 | 0.792 |
p-value 3 M | < 0.001 | < 0.001 | < 0.001 | ||
6 M | 370.4 ± 111.4 | 332.3 ± 61.5 | 311.7 ± 44.4 | 0.455 | 0.460 |
p-value 6 M | 0.001 | < 0.001 | < 0.001 | ||
SFCT (μm) | |||||
Baseline | 339.3 ± 63.4 | 343.7 ± 82.6 | 365.3 ± 62.5 | 0.532 | 0.783 |
3 M | 328.2 ± 71.9 | 319.3 ± 76.2 | 335.4 ± 57.5 | 0.746 | 0.597 |
p-value 3 M | 0.061 | < 0.001 | 0.003 | ||
6 M | 303.6 ± 66.4 | 326.9 ± 83.2 | 321.7 ± 66.2 | 0.156 | 0.157 |
p-value 6 M | < 0.001 | 0.001 | < 0.001 | ||
Baseline SND | |||||
Yes | 3 (11.5%) | 21 (28.4%) | 3 (13.6%) | 0.187 | 0.111 |
No | 23 (88.5%) | 53 (71.6%) | 19 (86.4%) | ||
Baseline EZ | |||||
Intact | 13 (50.0%) | 54 (72.9%) | 13 (59.1%) | 0.063 | 0.030 |
Disrupted | 13 (50.0%) | 19 (25.7%)c | 9 (40.9%) | ||
3 M EZ | |||||
Intact | 12 (46.2%) | 62 (83.8%) | 15 (68.2%) | 0.001 | < 0.001 |
Disrupted | 14 (53.8%) | 12 (16.2%) | 7 (31.8%) | ||
Laser | |||||
Yes | 22 (84.6%) | 36 (48.6%) | 10 (45.5%) | < 0.001 | 0.001 |
No | 4 (15.4%) | 38 (51.4%) | 12 (54.5%) | ||
Number of Injections | 4.4 ± 1.3 | 4.7 ± 1.3 | 4.8 ± 1.3 | 0.267 | 0.334 |